A new kind of CAR-T becomes a micro-pharmacy, eliminating glioblastoma in mice
In immunotherapy for cancer, the buzziest area of research is combinations: one checkpoint drug with another, say, or a checkpoint drug with chemotherapy. The latest brainstorm is an acronym lover’s dream team: CAR-Ts and BiTEs.
In a mouse study reported on Monday in Nature Biotechnology, the one-two punch vanquished glioblastoma, the incurable brain cancer that killed Sen. John McCain last August. You may be wondering:
